Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) is now available.
PharmAla Biotech Holdings Inc., a specialist in MDMA and MDXX-class psychedelic molecules, develops and manufactures clinical-grade compounds for research and patient treatments while advancing proprietary candidates such as its lead asset ALA-002. The company positions itself as a key supplier to clinical trials and regulated markets, emphasizing close collaboration with regulators as a competitive advantage.
PharmAla has reshaped its board of directors, accepting the resignation of long-time director Dr. Malik Slassi and appointing Montreal-based financial executive Lennie Ryer. Management highlighted Ryer’s deep experience in corporate finance, public-market transitions, and capital raising in life sciences and technology, signaling a push to strengthen governance and financial strategy as PharmAla moves into its next phase of growth.
The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.
Spark’s Take on TSE:MDMA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.
The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.
To see Spark’s full report on TSE:MDMA stock, click here.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA and its LaNeo-branded formulations. The company targets both alleviating the global shortage of clinical-grade MDMA for trials and selected commercial markets, and developing novel psychedelic-derived drug candidates under a regulatory-first approach.
Average Trading Volume: 154,846
Technical Sentiment Signal: Sell
Current Market Cap: C$10.89M
For an in-depth examination of MDMA stock, go to TipRanks’ Overview page.